

CLAIMS

1. An isolated molecule comprising an antibody variable region which specifically binds to an extracellular domain of a TEM protein selected from the group consisting of: 1, 9, 17, 19, and 44, as shown in SEQ ID NO: 196, 212, 230, 232, and 271, respectively.
2. The isolated molecule of claim 1 which is an in tact antibody molecule.
3. The isolated molecule of claim 1 which is a single chain variable region (ScFv).
4. The isolated molecule of claim 1 which is a monoclonal antibody.
5. The isolated molecule of claim 1 which is a humanized antibody.
6. The isolated molecule of claim 1 which is a human antibody.
7. The isolated molecule of claim 1 which is bound to a cytotoxic moiety.
8. The isolated molecule of claim 1 which is bound to a therapeutic moiety.
9. The isolated molecule of claim 1 which is bound to a detectable moiety.
10. The isolated molecule of claim 1 which is bound to an anti-tumor agent.
11. A method of inhibiting neoangiogenesis, comprising:

administering to a subject in need thereof an effective amount of an isolated molecule comprising an antibody variable region which specifically binds to an extracellular domain of a TEM protein selected from the group consisting of: 1, 9, 17, 19, 22, and 44, as shown in SEQ ID NO: 196, 212, 230, 232, 238, and 271, respectively, whereby neoangiogenesis is inhibited.

12. The method of claim 11 wherein the subject bears a vascularized tumor.

13. The method of claim 11 wherein the subject has polycystic kidney disease.

14. The method of claim 11 wherein the subject has diabetic retinopathy.

15. The method of claim 11 wherein the subject has rheumatoid arthritis.

16. The method of claim 11 wherein the subject has psoriasis.

17. A method of inhibiting tumor growth, comprising:

administering to a human subject bearing a tumor an effective amount of an isolated molecule comprising an antibody variable region which specifically binds to an extracellular domain of a TEM protein selected from the group consisting of: 1, 9, 17, 19, 22, and 44, as shown in SEQ ID NO: 196, 212, 230, 232, 238, and 271, respectively, whereby growth of the tumor is inhibited.